DK0815246T3 - Fremgangsmåder og sammensætninger til sekretion af heterologe polypeptider - Google Patents

Fremgangsmåder og sammensætninger til sekretion af heterologe polypeptider

Info

Publication number: DK0815246T3
Authority: DK; Denmark
Prior art keywords: secretion; polypeptide; interest; compositions; methods
Prior art date: 1995-03-01

Application number

DK96906659T

Other languages

English (en)

Inventor

Laura C Simmons

Daniel G Yansura

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-01

Filing date

1996-02-27

Publication date

2007-08-06

1996-02-27 Application filed by Genentech Inc filed Critical Genentech Inc

2007-08-06 Application granted granted Critical

2007-08-06 Publication of DK0815246T3 publication Critical patent/DK0815246T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Electrotherapy Devices (AREA)
External Artificial Organs (AREA)

DK96906659T 1995-03-01 1996-02-27 Fremgangsmåder og sammensætninger til sekretion af heterologe polypeptider DK0815246T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/398,615 US5840523A (en)	1995-03-01	1995-03-01	Methods and compositions for secretion of heterologous polypeptides
PCT/US1996/002858 WO1996027016A1 (en)	1995-03-01	1996-02-27	Methods and compositions for secretion of heterologous polypeptides

Publications (1)

Publication Number	Publication Date
DK0815246T3 true DK0815246T3 (da)	2007-08-06

Family

ID=23576066

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96906659T DK0815246T3 (da)	1995-03-01	1996-02-27	Fremgangsmåder og sammensætninger til sekretion af heterologe polypeptider

Country Status (18)

Country	Link
US (1)	US5840523A (da)
EP (1)	EP0815246B1 (da)
JP (1)	JP3375970B2 (da)
CN (1)	CN1154736C (da)
AT (1)	ATE358181T1 (da)
AU (1)	AU701476B2 (da)
BR (1)	BR9607464B1 (da)
CA (1)	CA2213813C (da)
DE (1)	DE69636996T2 (da)
DK (1)	DK0815246T3 (da)
ES (1)	ES2285711T3 (da)
FI (1)	FI120357B (da)
IL (1)	IL117314A0 (da)
NO (1)	NO324920B1 (da)
NZ (1)	NZ303619A (da)
RU (1)	RU2208639C2 (da)
WO (1)	WO1996027016A1 (da)
ZA (1)	ZA961688B (da)

Families Citing this family (813)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6242177B1 (en) *	1995-03-01	2001-06-05	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US6824780B1 (en) *	1999-10-29	2004-11-30	Genentech, Inc.	Anti-tumor antibody compositions and methods of use
DE60118370T2 (de)	2000-06-05	2006-12-07	Corixa Corp., Seattle	Leader-anteile zur erhöhung der sekretion von rekombinanten proteinen aus einer wirtzelle
DK1356052T3 (da) *	2000-12-14	2008-12-08	Genentech Inc	Produktion af hele antistoffer i prokaryotiske celler
US6979556B2 (en) *	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
KR100788092B1 (ko)	2001-06-20	2007-12-21	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP1427744B1 (en) *	2001-08-27	2007-12-26	Genentech, Inc.	A system for antibody expression and assembly
MXPA04002593A (es)	2001-09-18	2004-05-31	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumor.
KR100623128B1 (ko)	2002-01-02	2006-09-14	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
KR20040101502A (ko)	2002-04-16	2004-12-02	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
JP2005528905A (ja) *	2002-06-07	2005-09-29	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
AU2003287345A1 (en)	2002-10-31	2004-06-07	Genentech, Inc.	Methods and compositions for increasing antibody production
AR042485A1 (es)	2002-12-16	2005-06-22	Genentech Inc	Anticuerpo humanizado que se une al cd20 humano
US7575893B2 (en) *	2003-01-23	2009-08-18	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DK1633784T3 (da)	2003-05-09	2011-10-24	Diadexus Inc	OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
AU2004261980A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody CDR polypeptide sequences with restricted diversity
CA2534959A1 (en) *	2003-09-05	2005-03-31	Genentech, Inc.	Antibodies with altered effector functions
DE602004024921D1 (de)	2003-11-17	2010-02-11	Genentech Inc	Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
EP2275448A3 (en) *	2003-12-19	2013-02-06	Genentech, Inc.	Monovalent antibody fragments useful as therapeutics
AU2005244751A1 (en) *	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting B cell depletion
US20150017671A1 (en)	2004-04-16	2015-01-15	Yaping Shou	Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7476724B2 (en) *	2004-08-05	2009-01-13	Genentech, Inc.	Humanized anti-cmet antibodies
US7655229B2 (en) *	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
ZA200701783B (en) *	2004-09-02	2009-10-28	Genentech Inc	Anti-Fc-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) *	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
EP1789446A2 (en) *	2004-09-02	2007-05-30	Genentech, Inc.	Heteromultimeric molecules
HRP20120171T1 (hr)	2004-09-03	2012-03-31	Genentech	Humanizirani anti-beta 7 antagonisti i njihove uporabe
JP2008525041A (ja)	2004-12-22	2008-07-17	ジェネンテック・インコーポレーテッド	可溶性多膜貫通型タンパク質の産生方法
DK1841793T3 (da)	2005-01-07	2010-07-19	Diadexus Inc	Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
US7422899B2 (en) *	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070161089A1 (en) *	2005-11-08	2007-07-12	Genentech, Inc.	Method of Producing Pan-Specific Antibodies
EP1954719A2 (en)	2005-12-02	2008-08-13	Genentech Inc.	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
RU2470941C2 (ru) *	2005-12-02	2012-12-27	Дженентек, Инк.	Связывающие полипептиды и их применения
ES2535856T3 (es)	2005-12-15	2015-05-18	Genentech, Inc.	Métodos y composiciones para dirigirse a la poliubiquitina
EP1974041A2 (en) *	2006-01-06	2008-10-01	University Of Georgia Research Foundation, Inc.	Cyst nematode resistant transgenic plants
CA2647277A1 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
US8524865B2 (en)	2006-05-30	2013-09-03	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
UA94484C2 (uk)	2006-10-12	2011-05-10	Дженентек, Інк.	Антитіла до лімфотоксину-альфа
MX2009003938A (es)	2006-10-27	2009-04-24	Genentech Inc	Anticuerpos e inmunoconjugados y sus usos.
CA2670696A1 (en)	2006-11-27	2008-06-05	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
MX2009008430A (es)	2007-02-09	2009-10-28	Genentech Inc	Anticuerpos anti-robo4 y sus usos.
JP5761915B2 (ja)	2007-02-22	2015-08-12	ジェネンテック，インコーポレイテッド	炎症性腸疾患の検出方法
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
RS53595B1 (sr)	2007-07-16	2015-02-27	Genentech, Inc.	Anti-cd79b antitela i imunokonjugati i metode upotrebe
ES2528922T3 (es)	2007-07-16	2015-02-13	Genentech, Inc.	Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
RU2526512C2 (ru)	2007-09-26	2014-08-20	Чугаи Сейяку Кабусики Кайся	Модифицированная константная область антитела
WO2009062102A2 (en)	2007-11-07	2009-05-14	Genentech, Inc.	Compositions and methods for treatment of microbial disorders
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
MX2010005244A (es)	2007-11-12	2010-10-25	Theraclone Sciences Inc	Composiciones y métodos para la terapia y el diagnóstico de influenza.
WO2010135521A2 (en)	2009-05-20	2010-11-25	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
TWI580694B (zh)	2007-11-30	2017-05-01	建南德克公司	抗-ｖｅｇｆ抗體
AU2008345246B2 (en)	2007-12-28	2014-08-07	Genentech, Inc.	Anti-hedgehog antibodies
KR100958095B1 (ko) *	2007-12-31	2010-05-14	한국과학기술원	번역 동반 시스템을 이용한 항균 펩타이드의 대량 발현방법
IL287292B (en)	2008-01-31	2022-09-01	Genentech Inc	Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
JP2011513432A (ja) *	2008-03-06	2011-04-28	ジェネンテック，インコーポレイテッド	ｃ−ｍｅｔ及びＨＥＲアンタゴニストの併用療法
EP2257571B1 (en)	2008-03-10	2015-03-04	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
EP2318832B1 (en)	2008-07-15	2013-10-09	Academia Sinica	Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US8217149B2 (en)	2008-12-09	2012-07-10	Genentech, Inc.	Anti-PD-L1 antibodies, compositions and articles of manufacture
AU2009335788A1 (en)	2008-12-17	2011-07-07	Genentech, Inc.	Hepatitis C virus combination therapy
WO2010078376A2 (en)	2008-12-30	2010-07-08	Ventana Medical Systems, Inc.	Fc-specific polymer-conjugated antibodies and their diagnostic use
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
AR075896A1 (es)	2009-03-20	2011-05-04	Genentech Inc	Anticuerpos anti-her (factor de crecimiento epidermico)
WO2010120561A1 (en)	2009-04-01	2010-10-21	Genentech, Inc.	Anti-fcrh5 antibodies and immunoconjugates and methods of use
SI2417156T1 (sl)	2009-04-07	2015-06-30	Roche Glycart Ag	Trivalentna, bispecifiäśna protitelesa
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
CA2759506A1 (en) *	2009-04-23	2010-10-28	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
US8512704B2 (en)	2009-08-04	2013-08-20	Genentech, Inc.	Tmem27 antibody
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
MX2012003396A (es)	2009-09-16	2012-04-10	Genentech Inc	Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
EP2491058A1 (en)	2009-10-19	2012-08-29	F. Hoffmann-La Roche AG	Modulators of hepatocyte growth factor activator
US20110206704A1 (en) *	2009-10-19	2011-08-25	Genentech, Inc.	Methods and compositions for modulating hepatocyte growth factor activator
BR112012009409A2 (pt)	2009-10-22	2017-02-21	Genentech Inc	método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
CA2780143A1 (en)	2009-11-05	2011-05-12	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
NZ599173A (en)	2009-11-26	2013-06-28	Hoffmann La Roche	Marker protein for type 2 diabetes
TWI507524B (zh)	2009-11-30	2015-11-11	Genentech Inc	診斷及治療腫瘤之組合物及方法
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en)	2009-12-11	2011-06-16	Genentech, Inc.	Anti-vegf-c antibodies and methods using same
CN107095846A (zh)	2009-12-21	2017-08-29	霍夫曼-拉罗奇有限公司	抗体配制剂
SG183333A1 (en)	2010-02-18	2012-09-27	Genentech Inc	Neuregulin antagonists and use thereof in treating cancer
MA34057B1 (fr)	2010-02-23	2013-03-05	Genentech Inc	Compositions et methodes pour le diagnostic et le traitement d'une tumeur
JP6093692B2 (ja)	2010-03-24	2017-03-08	ジェネンテック，インコーポレイテッド	抗ｌｒｐ６抗体
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
JP2013533732A (ja)	2010-05-03	2013-08-29	ジェネンテック，インコーポレイテッド	腫瘍の診断と治療のための組成物と方法
DK2568976T3 (da)	2010-05-10	2016-01-11	Academia Sinica	Zanamivir-phosphonat-kongener med anti-influenzaaktivitet og fastlæggelse af oseltamivir-følsomhed hos influenzavira
EP4492053A3 (en)	2010-05-25	2025-03-19	F. Hoffmann-La Roche AG	Methods of purifying polypeptides
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
AU2011261362B2 (en)	2010-06-03	2016-06-09	Genentech, Inc.	Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
JP5940061B2 (ja)	2010-06-18	2016-06-29	ジェネンテック，インコーポレイテッド	抗ａｘｌ抗体及び使用方法
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
RU2571226C2 (ru)	2010-07-09	2015-12-20	Дженентек, Инк.	Антитела против нейропилина и способы их применения
WO2012007495A1 (en)	2010-07-15	2012-01-19	F. Hoffmann-La Roche Ag	Antibodies specifically binding to human tslpr and methods of use
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
WO2012017003A1 (en)	2010-08-05	2012-02-09	F. Hoffmann-La Roche Ag	Anti-mhc antibody anti-viral cytokine fusion protein
EP2603237A4 (en)	2010-08-12	2014-05-21	Theraclone Sciences Inc	ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
CA2806640A1 (en)	2010-08-13	2012-02-16	Roche Glycart Ag	Anti-tenascin-c a2 antibodies and methods of use
HUE036077T2 (hu)	2010-08-13	2018-06-28	Roche Glycart Ag	Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
JP2013537539A (ja)	2010-08-13	2013-10-03	ジェネンテック，インコーポレイテッド	疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
CN103068846B9 (zh)	2010-08-24	2016-09-28	弗·哈夫曼-拉罗切有限公司	包含二硫键稳定性Fv片段的双特异性抗体
RU2013110874A (ru)	2010-08-25	2014-09-27	Ф.Хоффманн-Ля Рош Аг	Антитела против il-18r1 и их применения
EP4549461A3 (en)	2010-08-31	2025-08-06	Theraclone Sciences, Inc.	Human immunodeficiency virus (hiv)-neutralizing antibodies
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
WO2012064836A1 (en)	2010-11-10	2012-05-18	Genentech, Inc.	Methods and compositions for neural disease immunotherapy
EP3447491A3 (en)	2010-12-16	2019-06-05	F. Hoffmann-La Roche AG	Diagnosis and treatments relating to th2 inhibition
TWI477513B (zh)	2010-12-20	2015-03-21	建南德克公司	抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
CA2820953A1 (en)	2010-12-22	2012-06-28	Genentech, Inc.	Anti-pcsk9 antibodies and methods of use
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
KR20130113493A (ko)	2011-01-03	2013-10-15	에프. 호프만-라 로슈 아게	항―ｄｉｇ 항체 및 펩티드에 접합되어 있는 디그옥시게닌의 복합체의 약학적 조성물
CA2827301A1 (en)	2011-02-14	2012-08-23	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
BR112013020338A2 (pt)	2011-02-28	2016-10-18	Hoffmann La Roche	proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
WO2012116926A1 (en)	2011-02-28	2012-09-07	F. Hoffmann-La Roche Ag	Antigen binding proteins
SG193402A1 (en)	2011-03-15	2013-10-30	Theraclone Sciences Inc	Compositions and methods for the therapy and diagnosis of influenza
SI2691417T2 (sl)	2011-03-29	2025-05-30	Roche Glycart Ag	FC variante protitelesa
CN103596983B (zh)	2011-04-07	2016-10-26	霍夫曼-拉罗奇有限公司	抗fgfr4抗体及使用方法
BR112013026423A2 (pt)	2011-04-20	2016-11-29	Roche Glycart Ag	método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
WO2012146630A1 (en)	2011-04-29	2012-11-01	F. Hoffmann-La Roche Ag	N-terminal acylated polypeptides, methods for their production and uses thereof
MX2013013054A (es)	2011-05-12	2014-02-20	Genentech Inc	Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
ES2628385T3 (es)	2011-05-16	2017-08-02	F. Hoffmann-La Roche Ag	Agonistas de FGFR1 y procedimientos de uso
MX2013014008A (es)	2011-06-15	2014-03-12	Hoffmann La Roche	Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).
RU2013158627A (ru)	2011-06-15	2015-07-20	Ф. Хоффманн-Ля Рош Аг	Антитела к рецептору человеческого эритропоэтина и способы их применения
AU2012274127B2 (en)	2011-06-22	2017-06-22	F. Hoffmann-La Roche Ag	Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
AR086823A1 (es)	2011-06-30	2014-01-22	Genentech Inc	Formulaciones de anticuerpo anti-c-met, metodos
JP2013040160A (ja)	2011-07-01	2013-02-28	Genentech Inc	自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
CA2842375A1 (en)	2011-08-17	2013-02-21	Erica Jackson	Neuregulin antibodies and uses thereof
KR20140048292A (ko)	2011-08-23	2014-04-23	로슈 글리카트 아게	항-mcsp 항체
WO2013033069A1 (en)	2011-08-30	2013-03-07	Theraclone Sciences, Inc.	Human rhinovirus (hrv) antibodies
CN103930781A (zh)	2011-09-15	2014-07-16	霍夫曼-拉罗奇有限公司	促进分化的方法
CA2845147A1 (en)	2011-09-23	2013-03-28	Roche Glycart Ag	Bispecific anti-egfr/anti igf-1r antibodies
US20130089562A1 (en)	2011-10-05	2013-04-11	Genenthech, Inc.	Methods of treating liver conditions using notch2 antagonists
CA2850032C (en)	2011-10-14	2022-06-07	Genentech, Inc.	Anti-htra1 antibodies and methods of use
BR112014008590A2 (pt)	2011-10-15	2017-10-24	Genentech Inc	métodos de uso de antagonistas de scd1
WO2013059531A1 (en)	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
BR112014010009A2 (pt)	2011-10-26	2017-04-25	Univ California	"anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"
JP6251682B2 (ja)	2011-10-28	2017-12-20	ジェネンテック，インコーポレイテッド	メラノーマ治療の治療の組み合わせ及び方法
RS63948B1 (sr)	2011-10-31	2023-02-28	Hoffmann La Roche	Formulacije anti-il13 antitela
CN104066748A (zh)	2011-11-21	2014-09-24	霍夫曼-拉罗奇有限公司	抗c-met抗体的纯化
AR089028A1 (es)	2011-11-29	2014-07-23	Genentech Inc	Composiciones y metodos para el analisis de cancer de prostata
AU2012318288B2 (en)	2011-12-01	2015-09-17	Ap Biosciences, Inc.	Protein inhibitors to complement and VEGF pathways and methods of use thereof
WO2013083497A1 (en)	2011-12-06	2013-06-13	F. Hoffmann-La Roche Ag	Antibody formulation
RU2756106C2 (ru)	2011-12-22	2021-09-28	Ф. Хоффманн-Ля Рош Аг	Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
US20160208284A1 (en)	2011-12-22	2016-07-21	Hoffmann-La Roche Inc.	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013091903A1 (en)	2011-12-22	2013-06-27	Novo Nordisk A/S	Anti-crac channel antibodies
BR112014013035A2 (pt)	2011-12-22	2018-10-09	Hoffmann La Roche	métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
WO2013096791A1 (en)	2011-12-23	2013-06-27	Genentech, Inc.	Process for making high concentration protein formulations
JP6684490B2 (ja)	2012-01-09	2020-04-22	ザ・スクリップス・リサーチ・インスティテュート	超長相補性決定領域及びその使用
CA2862979A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Humanized antibodies with ultralong cdr3s
PE20141561A1 (es)	2012-01-18	2014-11-12	Genentech Inc	Anticuerpos anti-lrp5 y metodos de uso
MX2014008699A (es)	2012-01-18	2014-11-21	Genentech Inc	Metodos para utilizar moduladores de fgf19.
TW201334789A (zh)	2012-01-31	2013-09-01	Genentech Inc	抗ｉｇｅ抗體及其使用方法
CN104105711B (zh)	2012-02-10	2018-11-30	弗·哈夫曼-拉罗切有限公司	单链抗体及其他异多聚体
WO2013120056A1 (en)	2012-02-11	2013-08-15	Genentech, Inc.	R-spondin translocations and methods using the same
WO2013120929A1 (en)	2012-02-15	2013-08-22	F. Hoffmann-La Roche Ag	Fc-receptor based affinity chromatography
PL2822587T3 (pl)	2012-03-08	2016-07-29	Hoffmann La Roche	Preparat przeciwciała abeta
CA2865082A1 (en)	2012-03-27	2013-10-03	Genentech, Inc.	Diagnosis and treatments relating to her3 inhibitors
EP2831119A1 (en)	2012-03-28	2015-02-04	F. Hoffmann-La Roche AG	Anti-hcmv idiotypic antibodies and uses thereof
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN104245937B (zh)	2012-04-17	2021-09-21	弗·哈夫曼-拉罗切有限公司	使用修饰的核酸表达多肽的方法
RU2014148162A (ru)	2012-05-01	2016-06-20	Дженентек, Инк.	Анти-pmel17 антитела и их иммуноконъюгаты
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
KR101843614B1 (ko)	2012-05-23	2018-03-29	제넨테크, 인크.	치료제의 선택 방법
US9266961B2 (en)	2012-06-15	2016-02-23	Genentech, Inc.	Anti-PCSK9 antibodies, formulations, dosing, and methods of use
RU2015101699A (ru)	2012-06-21	2016-08-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Слитые полипептиды и конъюгаты полипептида лиганда рецептора инкретина и fc-области с измененной fc-эффекторной функцией
WO2014001326A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
KR20150023889A (ko)	2012-06-27	2015-03-05	에프. 호프만-라 로슈 아게	2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
EP2867254B1 (en)	2012-06-27	2017-10-25	F. Hoffmann-La Roche AG	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CA2871112C (en)	2012-07-04	2020-05-12	F. Hoffmann-La Roche Ag	Covalently linked antigen-antibody conjugates
BR112014030844A2 (pt)	2012-07-04	2019-10-15	Hoffmann La Roche	anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
ES2600154T3 (es)	2012-07-04	2017-02-07	F. Hoffmann-La Roche Ag	Anticuerpos antiteofilina y métodos de uso
EP3578660A1 (en)	2012-07-05	2019-12-11	F. Hoffmann-La Roche AG	Expression and secretion system
BR112015000439A2 (pt)	2012-07-09	2017-12-19	Genentech Inc	imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
EP2869847B1 (en)	2012-07-09	2017-12-06	Genentech, Inc.	Immunoconjugates comprising anti-cd79b antibodies
US20140030280A1 (en)	2012-07-09	2014-01-30	Genentech, Inc.	Anti-cd79b antibodies and immunoconjugates
HK1209043A1 (en)	2012-07-09	2016-03-24	基因泰克公司	Immunoconjugates comprising anti-cd22 antibodies
PE20150361A1 (es)	2012-07-13	2015-03-14	Roche Glycart Ag	Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
KR20150038511A (ko)	2012-08-02	2015-04-08	에프. 호프만-라 로슈 아게	불활성 면역글로불린 Ｆｃ-영역을 갖는 Ｆｃ-융합체로서의 가용성 ＦｃＲ 의 생산 방법 및 그의 용도
EP2885311B1 (en)	2012-08-18	2020-01-01	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en)	2012-08-21	2017-01-17	Academia Sinica	Benzocyclooctyne compounds and uses thereof
KR20150052085A (ko)	2012-09-14	2015-05-13	에프. 호프만-라 로슈 아게	2개 이상의 상이한 단위를 포함하는 분자의 제조 및 선별 방법, 및 이의 용도
WO2014047311A1 (en)	2012-09-19	2014-03-27	Genentech, Inc.	Methods and compositions for preventing norleucine misincorporation into proteins
AR093378A1 (es)	2012-11-08	2015-06-03	Hoffmann La Roche	PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
BR112015010817A8 (pt)	2012-11-13	2018-01-23	Genentech Inc	anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
WO2014096015A1 (en)	2012-12-21	2014-06-26	F. Hoffmann-La Roche Ag	Disulfide-linked multivalent mhc class i comprising multi-function proteins
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
CN104936987A (zh)	2013-02-26	2015-09-23	罗切格利卡特公司	抗mcsp抗体
MY174679A (en)	2013-03-13	2020-05-06	Genentech Inc	Formulations with reduced oxidation
US20140314778A1 (en)	2013-03-13	2014-10-23	Genentech, Inc.	Formulations with reduced oxidation
US10653779B2 (en)	2013-03-13	2020-05-19	Genentech, Inc.	Formulations with reduced oxidation
NZ711567A (en)	2013-03-13	2020-04-24	Genentech Inc	Antibody formulations
RS60534B1 (sr)	2013-03-13	2020-08-31	Hoffmann La Roche	Formulacije sa smanjenom oksidacijom
AU2014244424A1 (en)	2013-03-14	2015-08-27	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
JP2016515132A (ja)	2013-03-14	2016-05-26	ジェネンテック，インコーポレイテッド	Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
EP2970452A2 (en)	2013-03-15	2016-01-20	AC Immune S.A.	Anti-tau antibodies and methods of use
MX2015011444A (es)	2013-03-15	2015-12-16	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
US20140283157A1 (en)	2013-03-15	2014-09-18	Diadexus, Inc.	Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
RS57393B1 (sr)	2013-03-15	2018-09-28	Hoffmann La Roche	Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu
AR095348A1 (es)	2013-03-15	2015-10-07	Genentech Inc	Medios de cultivo celular y métodos de producción de anticuerpos
MX2015012326A (es)	2013-03-15	2016-03-08	Genentech Inc	Anticuerpos anti-crth2 y su uso.
KR20210037745A (ko)	2013-03-15	2021-04-06	제넨테크, 인크.	항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
US20160053023A1 (en)	2013-04-09	2016-02-25	Annexon, Inc.	Methods of treatment for neuromyelitis optica
JP2016528167A (ja)	2013-04-29	2016-09-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ヒトＦｃＲｎ結合改変抗体及び使用方法
CN105164157B (zh)	2013-04-29	2024-05-28	豪夫迈·罗氏有限公司	Fc-受体结合的修饰的非对称抗体及使用方法
SG11201508910WA (en)	2013-04-29	2015-11-27	Hoffmann La Roche	Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
IL242088B2 (en)	2013-05-20	2023-12-01	Genentech Inc	Anti-transferrin receptor antibodies and methods of use
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
US9981030B2 (en)	2013-06-27	2018-05-29	Academia Sinica	Glycan conjugates and use thereof
SI3019240T1 (sl)	2013-07-09	2024-07-31	Annexon, Inc.	Protitelesa proti komplementnemu faktorju C1q in njihova uporaba
CN105377873B (zh)	2013-07-12	2021-03-30	豪夫迈·罗氏有限公司	阐明离子交换层析输入优化
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CN105814074B (zh)	2013-07-18	2020-04-21	图鲁斯生物科学有限责任公司	具有超长互补决定区的人源化抗体
EP2832854A1 (en)	2013-08-02	2015-02-04	F. Hoffmann-La Roche AG	Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
BR112016002829A2 (pt)	2013-08-12	2017-09-19	Genentech Inc	Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015035337A1 (en)	2013-09-06	2015-03-12	Academia Sinica	HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
KR20160055861A (ko)	2013-09-17	2016-05-18	오비아이 파머 인코퍼레이티드	암치료에서 면역반응을 유도하기 위한 탄수화물 백신의 조성물
KR20160055252A (ko)	2013-09-17	2016-05-17	제넨테크, 인크.	항-lgr5 항체의 사용 방법
PT3049441T (pt)	2013-09-27	2020-01-21	Hoffmann La Roche	Formulações de anticorpos anti-pdl1
US10414818B2 (en)	2013-09-27	2019-09-17	Roche Diagnostics Operations, Inc.	Thermus thermophilus SlyD FKBP domain specific antibodies
BR112016007635A2 (pt)	2013-10-11	2017-09-12	Genentech Inc	inibidores de nsp4 e métodos de uso
KR20160044060A (ko)	2013-10-11	2016-04-22	에프. 호프만-라 로슈 아게	다중특이적 도메인 교환된 통상의 가변 경쇄 항체
WO2015058132A2 (en)	2013-10-18	2015-04-23	Genentech, Inc.	Anti-rspo antibodies and methods of use
BR112016008694A2 (pt)	2013-10-23	2017-10-03	Genentech Inc	Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
JP2016538283A (ja)	2013-11-13	2016-12-08	ザイムワークス，インコーポレイテッド	Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
SI3071597T1 (sl)	2013-11-21	2020-11-30	F. Hoffmann-La Roche Ag	Anti alfa-sinukleinska protitelesa in postopki uporabe
ES3030987T3 (en)	2013-11-27	2025-07-03	Zymeworks Bc Inc	Bispecific antigen-binding constructs targeting her2
HRP20192052T1 (hr)	2013-12-09	2020-02-07	Allakos Inc.	Protutijela anti-siglec-8 te njihovi postupci i uporabe
EP3461845B1 (en)	2013-12-13	2020-09-16	Genentech, Inc.	Anti-cd33 antibodies and immunoconjugates
JP6980384B2 (ja)	2013-12-16	2021-12-15	ジェネンテック，インコーポレイテッド	１−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
FI3083686T4 (fi)	2013-12-17	2023-05-09		Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
CA2933881A1 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
BR112016013963A2 (pt)	2013-12-17	2017-10-10	Genentech Inc	terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
US10137170B2 (en)	2013-12-20	2018-11-27	Indiana University Research And Technology Corporation	Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
MX2016007208A (es)	2013-12-20	2016-07-21	Hoffmann La Roche	Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
EP3089996B1 (en)	2014-01-03	2021-07-28	F. Hoffmann-La Roche AG	Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3089758B1 (en)	2014-01-03	2021-01-27	F.Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
BR112016014945A2 (pt)	2014-01-03	2018-01-23	F. Hoffmann-La Roche Ag	conjugado, formulação farmacêutica e uso
BR112016015589A2 (pt)	2014-01-06	2017-10-31	Hoffmann La Roche	módulos de trânsito monovalentes para a barreira hematoencefálica
EP3835318B1 (en)	2014-01-15	2025-10-29	F. Hoffmann-La Roche AG	Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US9982041B2 (en)	2014-01-16	2018-05-29	Academia Sinica	Compositions and methods for treatment and detection of cancers
AU2015209154A1 (en)	2014-01-24	2017-02-16	Genentech, Inc.	Methods of using anti-STEAP1 antibodies and immunoconjugates
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
DK3102197T3 (da)	2014-02-04	2018-11-19	Genentech Inc	Smoothened-mutant og fremgangsmåder til anvendelse deraf
KR102476641B1 (ko)	2014-02-08	2022-12-09	제넨테크, 인크.	알츠하이머병의 치료 방법
EP3718563A1 (en)	2014-02-08	2020-10-07	F. Hoffmann-La Roche AG	Methods of treating alzheimer's disease
CA2936565C (en)	2014-02-12	2020-08-11	Genentech, Inc.	Anti-jagged1 antibodies and methods of use
MX2016010729A (es)	2014-02-21	2016-10-26	Genentech Inc	Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
WO2015131155A1 (en)	2014-02-28	2015-09-03	Allakos Inc.	Methods and compositions for treating siglec-8 associated diseases
WO2015139046A1 (en)	2014-03-14	2015-09-17	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
BR112016023417A2 (pt)	2014-03-21	2019-04-16	F. Hoffmann-La Roche Ag	predição in vitro de meia-vida in vivo
US20170107294A1 (en)	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
CN107002119A (zh)	2014-03-24	2017-08-01	豪夫迈·罗氏有限公司	使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
EP3129767B1 (en)	2014-03-27	2021-09-01	Academia Sinica	Reactive labelling compounds and uses thereof
JP6588461B2 (ja)	2014-03-31	2019-10-09	ジェネンテック，インコーポレイテッド	抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
PE20161571A1 (es)	2014-03-31	2017-02-07	Genentech Inc	Anticuerpos anti-ox40 y metodos de uso
EP4570917A3 (en)	2014-04-02	2025-09-03	F. Hoffmann-La Roche AG	Method for detecting multispecific antibody light chain mispairing
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
EP3145952A2 (en)	2014-05-22	2017-03-29	Genentech, Inc.	Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (ko)	2014-05-23	2017-01-11	제넨테크, 인크.	MiT 바이오마커 및 그의 사용 방법
CN106573971A (zh)	2014-05-27	2017-04-19	中央研究院	抗cd20醣抗体及其用途
AU2015267051B2 (en)	2014-05-27	2022-03-17	Academia Sinica	Fucosidase from bacteroides and methods using the same
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950440A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-her2 glycoantibodies and uses thereof
CN106714829A (zh)	2014-05-28	2017-05-24	中央研究院	抗TNF‑α醣抗体及其用途
MX2016016233A (es)	2014-06-11	2017-03-31	Genentech Inc	Anticuerpos anti-lgr5 y sus usos.
CA2947504A1 (en)	2014-06-26	2015-12-30	F. Hoffmann-La Roche Ag	Anti-brdu antibodies and methods of use
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112017000130A2 (pt)	2014-07-11	2018-01-09	Genentech Inc	método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
BR112017000497B1 (pt)	2014-07-11	2023-12-26	Ventana Medical Systems, Inc	Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
MX2017001531A (es)	2014-08-08	2017-05-15	Alector Llc	Anticuerpos anti-trem2 y metodos de uso de los mismos.
US9879042B2 (en)	2014-09-08	2018-01-30	Academia Sinica	Human iNKT cell activation using glycolipids
KR102508173B1 (ko)	2014-09-12	2023-03-10	제넨테크, 인크.	항-her2 항체 및 면역콘주게이트
JP6622293B2 (ja)	2014-09-12	2019-12-18	ジェネンテック，インコーポレイテッド	アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
EP3191518B1 (en)	2014-09-12	2020-01-15	Genentech, Inc.	Anti-b7-h4 antibodies and immunoconjugates
US9751946B2 (en)	2014-09-12	2017-09-05	Genentech, Inc.	Anti-CLL-1 antibodies and immunoconjugates
EP3193932B1 (en)	2014-09-15	2023-04-26	F. Hoffmann-La Roche AG	Antibody formulations
HK1243629A1 (zh)	2014-09-17	2018-07-20	基因泰克公司	包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
EP3689910A3 (en)	2014-09-23	2020-12-02	F. Hoffmann-La Roche AG	Method of using anti-cd79b immunoconjugates
CN107074938A (zh)	2014-10-16	2017-08-18	豪夫迈·罗氏有限公司	抗‑α‑突触核蛋白抗体和使用方法
SG11201703521UA (en)	2014-11-03	2017-05-30	Genentech Inc	Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CA2966523A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Assays for detecting t cell immune subsets and methods of use thereof
CN108064308B (zh)	2014-11-05	2023-06-09	豪夫迈·罗氏有限公司	细菌中产生双链蛋白的方法
SG11201703667SA (en)	2014-11-05	2017-06-29	Annexon Inc	Humanized anti-complement factor c1q antibodies and uses thereof
RU2739500C2 (ru)	2014-11-05	2020-12-25	Дженентек, Инк.	Способы получения двуцепочечных белков в бактериях
KR20170076697A (ko)	2014-11-06	2017-07-04	에프. 호프만-라 로슈 아게	개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
HUE045466T2 (hu)	2014-11-06	2019-12-30	Hoffmann La Roche	Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
MX2017006094A (es)	2014-11-10	2017-07-19	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos.
EP3552488A1 (en)	2014-11-10	2019-10-16	F. Hoffmann-La Roche AG	Animal model for nephropathy and agents for treating the same
EP3221360A1 (en)	2014-11-17	2017-09-27	F. Hoffmann-La Roche AG	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP6993228B2 (ja)	2014-11-19	2022-03-03	ジェネンテック，インコーポレイテッド	抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
US10508151B2 (en)	2014-11-19	2019-12-17	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
CN107108745B (zh)	2014-11-19	2021-01-12	基因泰克公司	抗bace1的抗体和其用于神经疾病免疫疗法的用途
DK3223848T3 (da)	2014-11-27	2025-03-03	Zymeworks Bc Inc	Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2
WO2016087416A1 (en)	2014-12-03	2016-06-09	F. Hoffmann-La Roche Ag	Multispecific antibodies
SG11201704449VA (en)	2014-12-05	2017-06-29	Genentech Inc	ANTI-CD79b ANTIBODIES AND METHODS OF USE
EP3230317A2 (en)	2014-12-10	2017-10-18	F. Hoffmann-La Roche AG	Blood brain barrier receptor antibodies and methods of use
RU2714963C2 (ru)	2014-12-17	2020-02-21	Ф. Хоффманн-Ля Рош Аг	Новые способы опосредованного ферментами конъюгирования полипептидов с использованием сортазы
CN107002114A (zh)	2014-12-18	2017-08-01	豪夫迈·罗氏有限公司	用于确定cdc引发抗体的测定试验和方法
IL278014B2 (en)	2014-12-19	2023-10-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
AR103162A1 (es)	2014-12-19	2017-04-19	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-c5 y métodos para su uso
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
AU2015378564A1 (en)	2015-01-24	2017-07-13	Academia Sinica	Novel glycan conjugates and methods of use thereof
CA2972731A1 (en)	2015-01-24	2016-07-28	Chi-Huey Wong	Cancer markers and methods of use thereof
EP3250590B1 (en)	2015-01-30	2021-09-15	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced anti-ssea4 antibody efficacy
CA2975875A1 (en)	2015-02-04	2016-08-11	Genentech, Inc.	Mutant smoothened and methods of using the same
SG10201907215QA (en)	2015-02-05	2019-09-27	Chugai Pharmaceutical Co Ltd	Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
CA2977285A1 (en)	2015-03-16	2016-09-22	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
JP6999421B2 (ja)	2015-04-07	2022-02-04	アレクトルエルエルシー	抗ソルチリン抗体及びその使用方法
JP2018512892A (ja)	2015-04-17	2018-05-24	エルサリーバイオテックＥｌｓａｌｙｓｂｉｏｔｅｃｈ	抗ｔｙｒｏ３抗体及びその使用
ES3007999T3 (en)	2015-04-21	2025-03-21	Genentech Inc	Compositions and methods for prostate cancer analysis
CN115932273A (zh)	2015-04-24	2023-04-07	豪夫迈·罗氏有限公司	鉴定包含结合多肽的细菌的方法
CN107709363A (zh)	2015-05-01	2018-02-16	基因泰克公司	掩蔽抗cd3抗体和使用方法
EP4238994A3 (en)	2015-05-11	2024-02-07	F. Hoffmann-La Roche AG	Compositions and methods of treating lupus nephritis
CN107646038B (zh)	2015-05-28	2021-08-20	基因泰克公司	用于检测抗cd3同二聚体的基于细胞的测定
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
AU2016271142A1 (en)	2015-05-29	2017-11-23	Genentech, Inc.	PD-L1 promoter methylation in cancer
JP2018516933A (ja)	2015-06-02	2018-06-28	ジェネンテック，インコーポレイテッド	抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
EP4465050A3 (en)	2015-06-05	2025-06-11	Genentech, Inc.	Anti-tau antibodies and methods of use
JP2018518483A (ja)	2015-06-08	2018-07-12	ジェネンテック，インコーポレイテッド	抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
JP2018521019A (ja)	2015-06-08	2018-08-02	ジェネンテック，インコーポレイテッド	抗ｏｘ４０抗体を使用して癌を治療する方法
AU2016276981B2 (en)	2015-06-12	2022-10-06	Alector Llc	Anti-CD33 antibodies and methods of use thereof
WO2016201389A2 (en)	2015-06-12	2016-12-15	Alector Llc	Anti-cd33 antibodies and methods of use thereof
JP2018524295A (ja)	2015-06-15	2018-08-30	ジェネンテック，インコーポレイテッド	抗体及び免疫複合体
EP3310378B1 (en)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anti-cll-1 antibodies and methods of use
EP3916018A1 (en)	2015-06-16	2021-12-01	Genentech, Inc.	Anti-cd3 antibodies and methods of use
CN107849132B (zh)	2015-06-16	2022-03-08	豪夫迈·罗氏有限公司	人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
JP2018524312A (ja)	2015-06-17	2018-08-30	ジェネンテック，インコーポレイテッド	抗ｈｅｒ２抗体及び使用方法
WO2016205567A1 (en)	2015-06-17	2016-12-22	Allakos Inc.	Methods and compositions for treating fibrotic diseases
IL256080B2 (en)	2015-06-17	2025-06-01	Genentech Inc	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
CN113929779B (zh)	2015-06-24	2025-02-25	豪夫迈·罗氏有限公司	人源化的抗-Tau(pS422)抗体和使用方法
UA123053C2 (uk)	2015-06-24	2021-02-10	Ф. Хоффманн-Ля Рош Аг	Антитіло до рецептора трансферину зі спеціально підібраною афінністю
CA2989936A1 (en)	2015-06-29	2017-01-05	Genentech, Inc.	Type ii anti-cd20 antibody for use in organ transplantation
EP3514174B1 (en)	2015-06-29	2021-03-31	Ventana Medical Systems, Inc.	Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
TR201816369T4 (tr)	2015-07-28	2018-11-21	Forschungszentrum Borstel Leibniz Lungenzentrum	Endotoksin tayinine yönelik iyileştirilmiş bakteriyel endotoksin testi.
TW202440903A (zh)	2015-08-04	2024-10-16	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法（一）
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3932953A1 (en)	2015-08-28	2022-01-05	F. Hoffmann-La Roche AG	Anti-hypusine antibodies and uses thereof
WO2017040301A1 (en)	2015-08-28	2017-03-09	Alector Llc	Anti-siglec-7 antibodies and methods of use thereof
KR20180050339A (ko)	2015-09-04	2018-05-14	오비아이 파머 인코퍼레이티드	글리칸 어레이 및 사용 방법
MY203894A (en)	2015-09-18	2024-07-23	Chugai Pharmaceutical Co Ltd	Il-8-binding antibodies and uses thereof
JP6904947B2 (ja)	2015-09-22	2021-07-21	スプリングバイオサイエンスコーポレーション	抗ｏｘ４０抗体及びその診断用途
KR102725051B1 (ko)	2015-09-23	2024-11-04	제넨테크, 인크.	항-vegf 항체의 최적화된 변이체들
CN108289954B (zh)	2015-09-24	2022-05-31	阿布维特罗有限责任公司	Hiv抗体组合物和使用方法
JP6861702B2 (ja)	2015-09-25	2021-04-21	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ソルターゼ・コンジュゲート化ループを含む組換え免疫グロブリン重鎖およびそのコンジュゲート
WO2017050874A1 (en)	2015-09-25	2017-03-30	F. Hoffmann-La Roche Ag	Process for producing thioesters employing a sortase a
KR20230125094A (ko)	2015-09-25	2023-08-28	제넨테크, 인크.	항-tigit 항체 및 이의 이용 방법
EP3353291B1 (en)	2015-09-25	2021-06-09	F. Hoffmann-La Roche AG	Novel soluble sortase a
JP6998863B2 (ja)	2015-09-25	2022-02-04	エフ．ホフマン－ラロシュアーゲー	深共融溶媒におけるソルターゼａを利用したアミド基転移
MA43023A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
MA43018B1 (fr)	2015-10-02	2021-11-30	Hoffmann La Roche	Anticorps anti-pd1 et procédés d'utilisation
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
RS62258B1 (sr)	2015-10-02	2021-09-30	Hoffmann La Roche	Bispecifična antitela specifična za pd1 i tim3
EP3150636A1 (en)	2015-10-02	2017-04-05	F. Hoffmann-La Roche AG	Tetravalent multispecific antibodies
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP7725185B2 (ja)	2015-10-06	2025-08-19	アレクトルエルエルシー	抗ｔｒｅｍ２抗体及びその使用方法
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
JP6949016B2 (ja)	2015-10-29	2021-10-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗バリアントＦｃ領域抗体および使用法
KR20180084817A (ko)	2015-10-29	2018-07-25	알렉터 엘엘씨	항-siglec-9 항체 및 이의 이용 방법
RU2750285C2 (ru)	2015-10-30	2021-06-25	Дженентек, Инк.	АНТИТЕЛА ПРОТИВ НtrА1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN115925962A (zh)	2015-10-30	2023-04-07	豪夫迈·罗氏有限公司	铰链修饰的抗体片段和其制备方法
WO2017075173A2 (en)	2015-10-30	2017-05-04	Genentech, Inc.	Anti-factor d antibodies and conjugates
CN108602884B (zh)	2015-11-08	2024-06-25	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
RU2761980C2 (ru)	2015-11-10	2021-12-14	Йейл Юниверсити	Композиции и способы лечения аутоиммунных заболеваний и рака
IL259256B2 (en)	2015-12-18	2023-02-01	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
CA3002422C (en)	2015-12-18	2024-04-16	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
AU2016380988B2 (en)	2015-12-30	2022-07-21	Genentech, Inc.	Formulations with reduced degradation of polysorbate
US20170239355A1 (en)	2015-12-30	2017-08-24	Genentech, Inc.	Use of tryptophan derivatives for protein formulations
ES2837428T3 (es)	2016-01-08	2021-06-30	Hoffmann La Roche	Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
CN114019170A (zh)	2016-01-20	2022-02-08	基因泰克公司	用于阿尔茨海默氏病的高剂量治疗
WO2017132279A1 (en)	2016-01-25	2017-08-03	Genentech, Inc.	Methods for assaying t-cell dependent bispecific antibodies
BR112018015480A2 (pt)	2016-01-29	2019-05-21	Sorrento Therapeutics, Inc.	proteínas de ligação ao antígeno que se ligam a pd-l1
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
US11472877B2 (en)	2016-03-04	2022-10-18	Alector Llc	Anti-TREM1 antibodies and methods of use thereof
US11357849B2 (en)	2016-03-07	2022-06-14	Musc Foundation For Research Development	Anti-nucleolin antibodies
US12128102B2 (en)	2016-03-08	2024-10-29	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
KR20180114210A (ko)	2016-03-08	2018-10-17	아카데미아 시니카	N-글리칸의 모듈 합성 방법 및 그의 어레이
EP3430054B1 (en)	2016-03-15	2021-12-29	Chugai Seiyaku Kabushiki Kaisha	Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
CN108700598A (zh)	2016-03-25	2018-10-23	豪夫迈·罗氏有限公司	多路总抗体和抗体缀合的药物量化测定法
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
US11041017B2 (en)	2016-03-29	2021-06-22	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
JP6727325B2 (ja)	2016-03-30	2020-07-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	改善されたソルターゼ
US20170319688A1 (en)	2016-04-14	2017-11-09	Genentech, Inc.	Anti-rspo3 antibodies and methods of use
AU2017252128B2 (en)	2016-04-22	2024-06-06	Obi Pharma, Inc.	Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
CR20180509A (es)	2016-05-02	2019-02-15	Hoffmann La Roche	Contorsbody - un ligante de diana monocatenario
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
CN109152843A (zh)	2016-05-20	2019-01-04	豪夫迈·罗氏有限公司	Protac抗体缀合物及其使用方法
CN109313200B (zh)	2016-05-27	2022-10-04	豪夫迈·罗氏有限公司	用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP6921943B2 (ja)	2016-06-06	2021-08-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	増加した眼球保持を伴う眼科用融合タンパク質
US10639378B2 (en)	2016-06-06	2020-05-05	Genentech, Inc.	Silvestrol antibody-drug conjugates and methods of use
KR102376582B1 (ko)	2016-06-17	2022-03-18	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
WO2017223405A1 (en)	2016-06-24	2017-12-28	Genentech, Inc.	Anti-polyubiquitin multispecific antibodies
JP6983824B2 (ja)	2016-07-04	2021-12-17	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	新規抗体フォーマット
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
KR20230117482A (ko)	2016-07-27	2023-08-08	오비아이 파머 인코퍼레이티드	면역원성/치료 글리칸 조성물 및 그의 용도
CN109415444B (zh)	2016-07-29	2024-03-01	中外制药株式会社	显示增加的备选fviii辅因子功能活性的双特异性抗体
CN110062767B (zh)	2016-07-29	2023-07-11	台湾浩鼎生技股份有限公司	人抗体、药物组合物和方法
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
JP7250674B2 (ja)	2016-08-08	2023-04-03	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がんの治療及び診断方法
ES3034020T3 (en)	2016-08-15	2025-08-12	Hoffmann La Roche	Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
US10538592B2 (en)	2016-08-22	2020-01-21	Cho Pharma, Inc.	Antibodies, binding fragments, and methods of use
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN116731197A (zh)	2016-09-19	2023-09-12	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
HRP20231015T1 (hr)	2016-09-23	2023-12-08	F. Hoffmann-La Roche Ag	Upotreba antagonista il-13 u liječenju atopičnog dermatitisa
EP3522933B1 (en)	2016-10-05	2021-12-15	F. Hoffmann-La Roche AG	Methods for preparing antibody drug conjugates
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
CN110366558A (zh)	2016-10-28	2019-10-22	班扬生物标记公司	针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
JP2019535250A (ja)	2016-10-29	2019-12-12	ジェネンテック，インコーポレイテッド	抗ｍｉｃ抗体及び使用方法
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
TWI822055B (zh)	2016-11-21	2023-11-11	台灣浩鼎生技股份有限公司	共軛生物分子、醫藥組成物及方法
WO2018091724A1 (en)	2016-11-21	2018-05-24	Cureab Gmbh	Anti-gp73 antibodies and immunoconjugates
CN110248959B (zh)	2016-12-07	2023-06-30	基因泰克公司	抗tau抗体和使用方法
EP3551220B1 (en)	2016-12-07	2025-01-29	Genentech, Inc.	Anti-tau antibodies and methods of use
MX2019006266A (es)	2016-12-21	2019-08-21	Hoffmann La Roche	Glucomanipulacion in vitro de anticuerpos.
MX2019006123A (es)	2016-12-21	2019-08-12	Hoffmann La Roche	Metodo para glicomanipulacion in vitro de anticuerpos.
JP6931058B2 (ja)	2016-12-21	2021-09-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗体のインビトロ糖鎖工学における酵素の再使用
CN108239150A (zh)	2016-12-24	2018-07-03	信达生物制药(苏州)有限公司	抗pcsk9抗体及其用途
JP7105238B2 (ja)	2017-01-18	2022-07-22	ジェネンテック，インコーポレイテッド	抗ｐｄ－ｌ１抗体に対するイディオタイプ抗体及びそれらの使用
TWI778018B (zh)	2017-02-10	2022-09-21	美商建南德克公司	抗類胰蛋白酶抗體、其組合物及其用途
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018162517A1 (en)	2017-03-10	2018-09-13	F. Hoffmann-La Roche Ag	Method for producing multispecific antibodies
AR111249A1 (es)	2017-03-22	2019-06-19	Genentech Inc	Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
JP7216006B2 (ja)	2017-03-22	2023-01-31	ジェネンテック，インコーポレイテッド	ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
CN108623686A (zh)	2017-03-25	2018-10-09	信达生物制药(苏州)有限公司	抗ox40抗体及其用途
KR20190133162A (ko)	2017-03-28	2019-12-02	제넨테크, 인크.	신경퇴행성 질병의 치료 방법
US11285207B2 (en)	2017-04-05	2022-03-29	Hoffmann-La Roche Inc.	Bispecific antibodies specifically binding to PD1 and LAG3
TWI707871B (zh)	2017-04-05	2020-10-21	瑞士商赫孚孟拉羅股份公司	抗lag3抗體
EP3615569A1 (en)	2017-04-25	2020-03-04	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
KR102769634B1 (ko)	2017-04-27	2025-02-19	테사로, 인코포레이티드	림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
EA201992626A1 (ru)	2017-05-05	2020-04-24	Аллакос Инк.	Способы и композиции для лечения аллергических заболеваний глаз
WO2018213097A1 (en)	2017-05-15	2018-11-22	University Of Rochester	Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
US11359014B2 (en)	2017-05-16	2022-06-14	Alector Llc	Anti-siglec-5 antibodies and methods of use thereof
AU2018281337B2 (en)	2017-06-06	2022-08-25	Relinia, Inc.	Single-chain TNF receptor 2 agonist fusion proteins
EP3655430A1 (en)	2017-07-19	2020-05-27	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
RS64419B1 (sr)	2017-08-03	2023-09-29	Alector Llc	Anti-trem2 antitela i postupci za njihovu upotrebu
CN110662765B (zh)	2017-08-03	2023-09-29	艾利妥	抗cd33抗体及其使用方法
CN111295394B (zh)	2017-08-11	2024-06-11	豪夫迈·罗氏有限公司	抗cd8抗体及其用途
WO2019036855A1 (en)	2017-08-21	2019-02-28	Adagene Inc.	Anti-cd137 molecules and use thereof
KR20200038996A (ko)	2017-08-21	2020-04-14	아다진 인크.	동적 인간 중쇄 항체 라이브러리
CA3072111A1 (en)	2017-08-21	2019-02-28	Adagene Inc.	Dynamic human antibody light chain libraries
CN109422811A (zh)	2017-08-29	2019-03-05	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
CN111315773A (zh)	2017-09-08	2020-06-19	马弗里克治疗公司	含有Fc区的条件性活化的结合部分
IL302613B2 (en)	2017-09-08	2025-04-01	Maverick Therapeutics Inc	Binding proteins are activated under limited conditions
CA3071236A1 (en)	2017-09-29	2019-04-04	Chugai Seiyaku Kabushiki Kaisha	Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
CN111372950B (zh)	2017-10-12	2024-11-05	免疫苏醒公司	Vegfr-抗体轻链融合蛋白
CA3079215A1 (en)	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of cd117+ cells
CA3078676A1 (en)	2017-10-30	2019-05-09	F. Hoffmann-La Roche Ag	Method for in vivo generation of multispecific antibodies from monospecific antibodies
EP3704146B1 (en)	2017-11-01	2021-12-15	F. Hoffmann-La Roche AG	Trifab-contorsbody
WO2019086394A1 (en)	2017-11-01	2019-05-09	F. Hoffmann-La Roche Ag	The compbody - a multivalent target binder
EP4640703A2 (en)	2017-11-14	2025-10-29	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s antibodies and methods of use
IL316155A (en)	2017-11-29	2024-12-01	Heidelberg Pharma Res	Compositions and Methods for the Depletion of CD5(PLUS) CELLS
EP3717517A1 (en)	2017-11-30	2020-10-07	H. Hoffnabb-La Roche Ag	Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
CN115925943A (zh)	2017-12-27	2023-04-07	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129137A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
WO2019129136A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
JP7369127B2 (ja)	2017-12-28	2023-10-25	ナンジンレジェンドバイオテックカンパニー，リミテッド	Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
EP3731865A1 (en)	2017-12-29	2020-11-04	F. Hoffmann-La Roche AG	Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
CN111886246B (zh)	2017-12-29	2024-12-17	艾莱克特有限责任公司	抗tmem106b抗体及其使用方法
CA3086879A1 (en)	2018-01-05	2019-07-11	Ac Immune Sa	Misfolded tdp-43 binding molecules
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
KR20250114571A (ko)	2018-01-15	2025-07-29	난징 레전드 바이오테크 씨오., 엘티디.	Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019143636A1 (en)	2018-01-16	2019-07-25	Lakepharma, Inc.	Bispecific antibody that binds cd3 and another target
AR114565A1 (es)	2018-01-26	2020-09-23	Genentech Inc	Proteínas de fusión fc il-22 y métodos de uso
CA3088763A1 (en)	2018-01-26	2019-08-01	Genentech, Inc.	Compositions and methods of use
US11472874B2 (en)	2018-01-31	2022-10-18	Alector Llc	Anti-MS4A4A antibodies and methods of use thereof
CA3081125C (en)	2018-02-01	2025-09-16	Innovent Biologics (Suzhou) Co., Ltd.	All-Human Single-Chain Variable Fragment Anti-Antigen for B Lymphocyte Maturation (BCMA), and Associated Application
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Anti-ctla4 antibodies and methods of making and using the same
CN118772288A (zh)	2018-02-08	2024-10-15	豪夫迈·罗氏有限公司	双特异性抗原结合分子和使用方法
CA3091646A1 (en)	2018-02-14	2019-08-22	Abba Therapeutics Ag	Anti-human pd-l2 antibodies
RU2020128111A (ru)	2018-02-21	2022-03-21	Дженентек, Инк.	ВЕДЕНИЕ БЕЛКОВ СЛИЯНИЯ IL-22 Fc ДЛЯ ЛЕЧЕНИЯ
CA3092108A1 (en)	2018-02-26	2019-08-29	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3533459A1 (en)	2018-03-02	2019-09-04	Diaccurate	Anti-pla2-gib antibodies and the uses thereof
EP3533460A1 (en)	2018-03-02	2019-09-04	Diaccurate	Therapeutic anti-spla2-gib antibodies and the uses thereof
WO2019170677A1 (en)	2018-03-05	2019-09-12	Etablissement Francais Du Sang	Recombinant single chain immunoglobulins
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
TWI887899B (zh)	2018-03-15	2025-06-21	日商中外製藥股份有限公司	對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
US11958903B2 (en)	2018-03-30	2024-04-16	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against LAG-3 and uses thereof
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
AR115052A1 (es)	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
FR3080621B1 (fr)	2018-04-26	2022-12-09	Univ Limoges	Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
US12084489B2 (en)	2018-05-02	2024-09-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
WO2019213384A1 (en)	2018-05-03	2019-11-07	University Of Rochester	Anti-influenza neuraminidase monoclonal antibodies and uses thereof
CR20200566A (es)	2018-05-25	2021-02-19	Alector Llc	Anticuerpos anti-sirpa y metodos de utilización de los mismos
EP3805400A4 (en)	2018-06-04	2022-06-29	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
WO2019235581A1 (ja)	2018-06-06	2019-12-12	国立大学法人大阪大学	Ｒｅｇｎａｓｅ－１が関与する疾患の治療および／または予防方法
JP7382970B2 (ja)	2018-06-08	2023-11-17	アレクトルエルエルシー	抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
AU2019288728A1 (en)	2018-06-23	2021-01-14	Genentech, Inc.	Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020006176A1 (en)	2018-06-27	2020-01-02	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
CA3099176A1 (en)	2018-06-29	2020-01-02	Alector Llc	Anti-sirp-beta1 antibodies and methods of use thereof
CN112955465A (zh)	2018-07-03	2021-06-11	马伦戈治疗公司	抗tcr抗体分子及其用途
PE20210186A1 (es)	2018-07-13	2021-02-02	Alector Llc	Anticuerpos anti-sortilina y metodos para su uso
MX2021000268A (es)	2018-07-17	2021-06-08	Humabs Biomed Sa	Anticuerpos contra especies de campylobacter.
MX2021000745A (es)	2018-07-20	2021-03-26	Surface Oncology Inc	Composiciones anti-cd112r y metodos.
AU2019311077B2 (en)	2018-07-23	2025-05-29	Heidelberg Pharma Research Gmbh	Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
CN112135626B (zh)	2018-07-25	2023-05-23	信达生物制药(苏州)有限公司	抗tigit抗体及其用途
EA202190183A1 (ru)	2018-07-27	2021-05-18	Алектор Ллс	Антитела к siglec-5 и способы их применения
CN113286824A (zh)	2018-08-03	2021-08-20	中外制药株式会社	包含两个彼此连接的抗原结合结构域的抗原结合分子
JP7542521B2 (ja)	2018-08-08	2024-08-30	ジェネンテック，インコーポレイテッド	タンパク質製剤のためのトリプトファン誘導体及びｌ－メチオニンの使用
MX2021001431A (es)	2018-08-10	2021-05-12	Chugai Pharmaceutical Co Ltd	Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
AU2019331018A1 (en)	2018-08-31	2021-03-11	Alector Llc	Anti-cd33 antibodies and methods of use thereof
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
ES2955032T3 (es)	2018-09-21	2023-11-28	Hoffmann La Roche	Métodos de diagnóstico para el cáncer de mama triple negativo
WO2020081493A1 (en)	2018-10-16	2020-04-23	Molecular Templates, Inc.	Pd-l1 binding proteins
CN113366021A (zh)	2018-10-23	2021-09-07	格雷卡迪亚尔诊断有限公司	糖基化Apo J特异性抗体及其用途
CN113056287A (zh)	2018-10-24	2021-06-29	豪夫迈·罗氏有限公司	缀合的化学降解诱导剂及使用方法
CN111116745B (zh)	2018-11-01	2022-10-14	上海新理念生物医药科技有限公司	抗CD79b抗体、其药物偶联物及其应用
JP7499760B2 (ja)	2018-11-02	2024-06-14	アネクソン，インコーポレーテッド	脳損傷を治療するための組成物及び方法
WO2020096959A1 (en)	2018-11-05	2020-05-14	Genentech, Inc.	Methods of producing two chain proteins in prokaryotic host cells
US12098195B2 (en)	2018-11-27	2024-09-24	Innovent Biologics (Suzhou) Co., Ltd.	Anti-IL-23p19 antibody and use thereof in treating diseases
WO2020117257A1 (en)	2018-12-06	2020-06-11	Genentech, Inc.	Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
JP2022513198A (ja)	2018-12-10	2022-02-07	ジェネンテック，インコーポレイテッド	Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
HRP20231440T1 (hr)	2018-12-19	2024-03-01	Humabs Biomed Sa	Protutijela koja neutraliziraju virus hepatitisa b i njihova upotreba
WO2020132230A2 (en)	2018-12-20	2020-06-25	Genentech, Inc.	Modified antibody fcs and methods of use
CN119708247A (zh)	2018-12-21	2025-03-28	豪夫迈·罗氏有限公司	与VEGF和IL-1β结合的抗体及其使用方法
CN113272327A (zh)	2018-12-30	2021-08-17	豪夫迈·罗氏有限公司	抗兔cd19抗体及其使用方法
CN119490582A (zh)	2019-01-22	2025-02-21	豪夫迈·罗氏有限公司	免疫球蛋白a抗体以及制备和使用方法
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
CN119661722A (zh)	2019-02-21	2025-03-21	马伦戈治疗公司	结合t细胞相关癌细胞的多功能分子及其用途
CN119039441A (zh)	2019-02-21	2024-11-29	马伦戈治疗公司	与nkp30结合的抗体分子及其用途
JP2022521773A (ja)	2019-02-27	2022-04-12	ジェネンテック，インコーポレイテッド	抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
EP4592313A3 (en)	2019-03-05	2025-11-19	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
EP3934761A1 (en)	2019-03-05	2022-01-12	Takeda Pharmaceutical Company Limited	Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
EP3935385A1 (en)	2019-03-08	2022-01-12	F. Hoffmann-La Roche AG	Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
CN121159688A (zh)	2019-03-19	2025-12-19	中外制药株式会社	包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
EP3956664A1 (en)	2019-04-18	2022-02-23	Genentech, Inc.	Antibody potency assay
BR112021020867A2 (pt)	2019-04-19	2022-01-04	Genentech Inc	Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
JP2022530026A (ja)	2019-04-24	2022-06-27	ハイデルベルクファルマリサーチゲゼルシャフトミットベシュレンクテルハフツング	アマトキシン抗体薬物複合体及びその使用
TW202106715A (zh)	2019-04-25	2021-02-16	瑞士商赫孚孟拉羅股份公司	藉由多肽鏈交換活化之治療性多特異性多肽
CN113767114A (zh)	2019-04-25	2021-12-07	豪夫迈·罗氏有限公司	半衰期延长的可活化治疗性多特异性多肽
MX2021012871A (es)	2019-04-25	2021-11-17	Hoffmann La Roche	Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
EP3968993A1 (en)	2019-05-14	2022-03-23	F. Hoffmann-La Roche AG	Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
MX2021014274A (es)	2019-05-23	2022-01-06	Ac Immune Sa	Moleculas de union anti-tdp-43 y usos de las mismas.
CA3140023A1 (en)	2019-06-11	2020-12-17	Alector Llc	Anti-sortilin antibodies for use in therapy
PH12021552960A1 (en)	2019-07-10	2022-07-25	Chugai Pharmaceutical Co Ltd	Claudin-6 binding molecules and uses thereof
AR119382A1 (es)	2019-07-12	2021-12-15	Hoffmann La Roche	Anticuerpos de pre-direccionamiento y métodos de uso
KR20220058540A (ko)	2019-07-31	2022-05-09	알렉터 엘엘씨	항-ms4a4a 항체 및 이의 사용 방법
TWI832183B (zh)	2019-08-06	2024-02-11	香港商新旭生技股份有限公司	結合至病理性tau種類之抗體及其用途
EP3786180A1 (en)	2019-08-27	2021-03-03	Diaccurate	Antibodies and the uses thereof
IL290752B1 (en)	2019-08-29	2025-10-01	Vir Biotechnology Inc	Preparations and methods for treating influenza A infection
MX2022002231A (es)	2019-08-29	2022-03-22	Vir Biotechnology Inc	Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
EP4025608A1 (en)	2019-09-04	2022-07-13	F. Hoffmann-La Roche AG	Cd8 binding agents and uses thereof
MX2022002963A (es)	2019-09-12	2022-04-06	Genentech Inc	Composiciones y metodos para tratar nefritis lupica.
WO2021055816A1 (en)	2019-09-18	2021-03-25	Molecular Templates, Inc.	Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
AU2020349509A1 (en)	2019-09-18	2022-03-31	Genentech, Inc.	Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
AU2020350769A1 (en)	2019-09-20	2022-03-31	Denali Therapeutics Inc.	Anti-alpha-synuclein antibodies and methods of use thereof
CR20220127A (es)	2019-09-27	2022-05-27	Genentech Inc	Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
US20220281997A1 (en)	2019-09-27	2022-09-08	Nanjing GenScript Biotech Co., Ltd.	Anti-VHH Domain Antibodies and Use Thereof
EP4034160A1 (en)	2019-09-27	2022-08-03	Janssen Biotech, Inc.	Anti-ceacam antibodies and uses thereof
CA3153880A1 (en)	2019-10-18	2020-06-09	Juana Elva HERNANDEZ MONTALVO	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN115551594A (zh)	2019-10-24	2022-12-30	米诺陶治疗公司	经细胞因子修饰的嵌合抗体及其使用方法
US20220389103A1 (en)	2019-11-06	2022-12-08	Genentech, Inc.	Diagnostic and therapeutic methods for treatment of hematologic cancers
CN117106070B (zh)	2019-11-11	2024-06-11	珠海泰诺麦博制药股份有限公司	抗水痘-带状疱疹病毒的抗体
EP4058479A4 (en)	2019-11-15	2024-02-28	University of Tennessee Research Foundation	MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
WO2021094508A1 (en)	2019-11-15	2021-05-20	F. Hoffmann-La Roche Ag	Prevention of visible particle formation in aqueous protein solutions
WO2021113655A1 (en)	2019-12-05	2021-06-10	Alector Llc	Methods of use of anti-trem2 antibodies
CA3081503A1 (en)	2019-12-06	2021-06-06	Zymeworks Inc.	Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
AU2020403021A1 (en)	2019-12-12	2022-06-23	Alector Llc	Methods of use of anti-CD33 antibodies
CA3160210A1 (en)	2019-12-13	2021-06-17	Alector Llc	Anti-mertk antibodies and methods of use thereof
KR20220113790A (ko)	2019-12-13	2022-08-16	제넨테크, 인크.	항-ly6g6d 항체 및 사용 방법
WO2021122733A1 (en)	2019-12-18	2021-06-24	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
EP4081294A2 (en)	2019-12-23	2022-11-02	Genentech, Inc.	Apolipoprotein l1-specific antibodies and methods of use
IL294226B2 (en)	2019-12-27	2025-05-01	Chugai Pharmaceutical Co Ltd	Anti-CTLA-4 antibodies and their use
GB2609554B (en)	2020-01-03	2025-08-20	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
CN116655799A (zh)	2020-01-15	2023-08-29	特鲁提诺生物科学公司	包括可切割接头的il-2细胞因子前药
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CA3165319A1 (en)	2020-01-31	2021-08-05	Vincent K. Tuohy	Anti-mullerian hormone receptor 2 antibodies and methods of use
BR112022015374A2 (pt)	2020-02-03	2022-10-11	Vir Biotechnology Inc	Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
KR20220140786A (ko)	2020-02-10	2022-10-18	상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드	클라우딘18.2 항체 및 그것의 사용
CA3167299A1 (en)	2020-02-10	2021-08-19	Shanghai Escugen Biotechnology Co., Ltd.	Cldn18.2 antibody and use thereof
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
CA3167851A1 (en)	2020-02-24	2021-09-02	Francesca CIGNARELLA	Methods of use of anti-trem2 antibodies
US11168128B2 (en)	2020-02-26	2021-11-09	Vir Biotechnology, Inc.	Antibodies against SARS-CoV-2 and methods of using the same
EP4118114A1 (en)	2020-03-13	2023-01-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en)	2020-03-19	2024-03-05	Genentech, Inc.	Isoform-selective anti-TGFβ antibodies and methods of use
PE20230414A1 (es)	2020-03-24	2023-03-07	Genentech Inc	Agentes de fijacion a tie2 y metodos de uso
EP4126940A1 (en)	2020-03-30	2023-02-08	F. Hoffmann-La Roche AG	Antibody that binds to vegf and pdgf-b and methods of use
EP4126937A1 (en)	2020-03-31	2023-02-08	Alector LLC	Anti-mertk antibodies and methods of use thereof
KR20220161375A (ko)	2020-03-31	2022-12-06	추가이 세이야쿠 가부시키가이샤	다중 특이성 항원 결합 분자를 제조하기 위한 방법
CA3170570A1 (en)	2020-04-01	2021-10-07	James J. KOBIE	Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
CN115380210A (zh)	2020-04-02	2022-11-22	中外制药株式会社	含多特异性抗原结合分子的组合物中的杂质分子的分析方法
WO2021203053A1 (en)	2020-04-03	2021-10-07	Vir Biotechnology, Inc.	Immunotherapy targeting a conserved region in sars coronaviruses
EP4126953A2 (en)	2020-04-03	2023-02-08	Alector LLC	Methods of use of anti-trem2 antibodies
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
EP4135846A1 (en)	2020-04-14	2023-02-22	VIR Biotechnology, Inc.	Antibodies against sars-cov-2 and methods of using the same
CN113527482B (zh)	2020-04-17	2023-07-21	珠海泰诺麦博制药股份有限公司	抗人神经生长因子的抗体
IL297541A (en)	2020-04-24	2022-12-01	Genentech Inc	Methods for using anti-cd79b immunoconjugates
CR20220531A (es)	2020-04-24	2022-11-28	Hoffmann La Roche	Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
US11634477B2 (en)	2020-04-28	2023-04-25	The Rockefeller University	Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
CN115461375A (zh)	2020-04-30	2022-12-09	基因泰克公司	Kras特异性抗体及其用途
IL297830A (en)	2020-05-03	2023-01-01	Levena Suzhou Biopharma Co Ltd	Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
MX2022013886A (es)	2020-05-08	2022-11-30	Vir Biotechnology Inc	Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
CN115605184A (zh)	2020-05-15	2023-01-13	豪夫迈·罗氏有限公司（Ch）	防止胃肠外蛋白质溶液中的可见颗粒形成
CN115605185A (zh)	2020-05-19	2023-01-13	豪夫迈·罗氏有限公司（Ch）	螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
WO2021247925A1 (en)	2020-06-03	2021-12-09	Vir Biotechnology, Inc.	Structure-guided immunotherapy against sars-cov-2
BR112022024996A2 (pt)	2020-06-08	2022-12-27	Hoffmann La Roche	Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
TW202207983A (zh)	2020-06-12	2022-03-01	美商維爾生物科技股份有限公司	用於sars-cov-2感染的抗體療法
CA3181820A1 (en)	2020-06-16	2021-12-23	Genentech, Inc.	Methods and compositions for treating triple-negative breast cancer
WO2021257124A1 (en)	2020-06-18	2021-12-23	Genentech, Inc.	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
BR112022026316A2 (pt)	2020-06-24	2023-03-07	Vir Biotechnology Inc	Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
JP2023532764A (ja)	2020-07-07	2023-07-31	エフ．ホフマン－ラロシュアーゲー	治療用タンパク質製剤の安定剤としての代替界面活性剤
IL298921A (en)	2020-07-10	2023-02-01	Hoffmann La Roche	Antibodies which bind to cancer cells and target radionuclides to said cells
EP3939999A1 (en)	2020-07-14	2022-01-19	Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
BR112023000707A2 (pt)	2020-07-14	2023-01-31	Hoffmann La Roche	Ensaio de ligação para uma combinação de dose fixa, proteína, kits, composições e métodos para avaliar uma composição de dose fixa, fazer uma composição e para analisar o teor de proteína de uma combinação de dose fixa
IL299799A (en)	2020-07-17	2023-03-01	Genentech Inc	Anti-NOTCH2 antibodies and methods of use
PE20231104A1 (es)	2020-07-21	2023-07-19	Genentech Inc	Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
MX2023001157A (es)	2020-07-31	2023-02-22	Genentech Inc	Formulaciones de anticuerpo anti-integrina beta7 y dispositivos.
WO2022031876A1 (en)	2020-08-07	2022-02-10	Genentech, Inc.	Flt3 ligand fusion proteins and methods of use
EP4196162A1 (en)	2020-08-14	2023-06-21	AC Immune SA	Humanized anti-tdp-43 binding molecules and uses thereof
WO2022043517A2 (en)	2020-08-27	2022-03-03	Cureab Gmbh	Anti-golph2 antibodies for macrophage and dendritic cell differentiation
JP7158626B1 (ja)	2020-09-04	2022-10-21	エフ．ホフマン－ラロシュアーゲー	Ｖｅｇｆ－ａ及びａｎｇ２に結合する抗体及び使用方法
JP2023542528A (ja)	2020-09-24	2023-10-10	フレッドハッチンソンキャンサーセンター	Ｓｏｘ２抗原を標的とする免疫療法
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
WO2022067269A2 (en)	2020-09-28	2022-03-31	Humabs Biomed Sa	Antibodies against sars-cov-2
JP2023544407A (ja)	2020-10-05	2023-10-23	ジェネンテック，インコーポレイテッド	抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
JP2023545821A (ja)	2020-10-16	2023-10-31	ジェネンテック，インコーポレイテッド	抗ｉＣａｓｐａｓｅ切断基質抗体および使用方法
WO2022084400A1 (en)	2020-10-20	2022-04-28	Kantonsspital St. Gallen	Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
AR123855A1 (es)	2020-10-20	2023-01-18	Genentech Inc	Anticuerpos anti-mertk conjugados con peg y métodos de uso
WO2022098870A1 (en)	2020-11-04	2022-05-12	The Rockefeller University	Neutralizing anti-sars-cov-2 antibodies
MX2023005130A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
US20220153842A1 (en)	2020-11-04	2022-05-19	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
WO2022098638A2 (en)	2020-11-04	2022-05-12	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US20240141021A1 (en)	2020-11-23	2024-05-02	Vir Biotechnology, Inc.	Anti-influenza antibodies and combinations thereof
EP4247495A1 (en)	2020-11-23	2023-09-27	VIR Biotechnology, Inc.	Broadly neutralizing antibodies against influenza neuraminidase
KR20230135569A (ko)	2020-11-23	2023-09-25	비르 바이오테크놀로지, 인코포레이티드	인플루엔자 a 바이러스에 대한 항체
WO2022115486A1 (en)	2020-11-25	2022-06-02	Vir Biotechnology, Inc.	Antibodies that bind to multiple betacoronaviruses
KR20230117169A (ko)	2020-12-02	2023-08-07	알렉터 엘엘씨	항-소르틸린 항체의 사용 방법
WO2022122652A1 (en)	2020-12-07	2022-06-16	UCB Biopharma SRL	Antibodies against interleukin-22
PE20231953A1 (es)	2020-12-07	2023-12-06	UCB Biopharma SRL	Anticuerpos multiespecificos y combinaciones de anticuerpos
CA3200900A1 (en)	2020-12-08	2022-06-16	Davide Corti	Antibodies and methods for treatment of influenza a infection
CR20230263A (es)	2020-12-17	2023-08-21	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de estos
WO2022140797A1 (en)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines and uses thereof
WO2022135467A1 (zh)	2020-12-23	2022-06-30	信达生物制药(苏州)有限公司	抗b7-h3抗体及其用途
JP2024503826A (ja)	2021-01-06	2024-01-29	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ｔ細胞二重特異性抗体を用いる併用療法
MX2023008084A (es)	2021-01-12	2023-07-13	Hoffmann La Roche	Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas.
US12060411B2 (en)	2021-01-15	2024-08-13	The Rockefeller University	Neutralizing anti-SARS-CoV-2 antibodies
JP2024504372A (ja)	2021-01-22	2024-01-31	エルピス・バイオファーマシューティカルズ	抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質
WO2022159842A1 (en)	2021-01-25	2022-07-28	Vir Biotechnology, Inc.	Antibody combination therapies for sars-cov-2 infection
TW202245838A (zh)	2021-01-26	2022-12-01	美商維爾生物科技股份有限公司	用於治療b型肝炎病毒感染的組成物及方法
WO2022162587A1 (en)	2021-01-27	2022-08-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
AU2022212599A1 (en)	2021-01-28	2023-08-17	Universität Ulm	Method and means for modulating b-cell mediated immune responses
CN117120084A (zh)	2021-01-28	2023-11-24	维肯芬特有限责任公司	用于调节b细胞介导的免疫应答的方法和手段
WO2022162203A1 (en)	2021-01-28	2022-08-04	Vaccinvent Gmbh	Method and means for modulating b-cell mediated immune responses
WO2022169872A1 (en)	2021-02-03	2022-08-11	Genentech, Inc.	Multispecific binding protein degrader platform and methods of use
WO2022166846A1 (zh)	2021-02-04	2022-08-11	信达生物制药(苏州)有限公司	抗tnfr2抗体及其用途
JP2024508658A (ja)	2021-02-04	2024-02-28	ジェヌーヴインク．	抗ｐｄ－１抗体及びその用途
TW202246317A (zh)	2021-02-09	2022-12-01	瑞士商休曼生物醫藥股份公司	針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
EP4301418A1 (en)	2021-03-03	2024-01-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates comprising an anti-bcma antibody
WO2022192898A2 (en)	2021-03-10	2022-09-15	Immunowake Inc.	Immunomodulatory molecules and uses thereof
CN117062839A (zh)	2021-03-12	2023-11-14	基因泰克公司	抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
TW202300521A (zh)	2021-03-15	2023-01-01	美商建南德克公司	治療狼瘡性腎炎的組成物及方法
CA3213295A1 (en)	2021-03-17	2022-09-22	Molecular Templates, Inc.	Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US20240174746A1 (en)	2021-03-18	2024-05-30	Alector Llc	Anti-tmem106b antibodies and methods of use thereof
WO2022197877A1 (en)	2021-03-19	2022-09-22	Genentech, Inc.	Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204202A1 (en)	2021-03-23	2022-09-29	Vir Biotechnology, Inc.	Antibodies that bind to multiple sarbecoviruses
US20240166738A1 (en)	2021-03-23	2024-05-23	Alector Llc	Anti-tmem106b antibodies for treating and preventing coronavirus infections
JP2024511424A (ja)	2021-03-25	2024-03-13	ダイナミキュアバイオテクノロジーエルエルシー	抗ｉｇｆｂｐ７構築物およびその使用
EP4067376A1 (en)	2021-03-30	2022-10-05	Diaccurate	Anti-pla2g1b monoclonal antibodies and uses thereof
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
US20250197525A1 (en)	2021-04-28	2025-06-19	Minotaur Therapeutics, Inc.	Humanized chimeric bovine antibodies and methods of use
EP4330282A1 (en)	2021-04-30	2024-03-06	F. Hoffmann-La Roche AG	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
CA3218933A1 (en)	2021-05-03	2022-11-10	UCB Biopharma SRL	Antibodies
EP4334343A2 (en)	2021-05-06	2024-03-13	The Rockefeller University	Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CA3218170A1 (en)	2021-05-12	2022-11-17	Jamie Harue HIRATA	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
TW202306993A (zh)	2021-05-14	2023-02-16	美商建南德克公司	Ｔｒｅｍ２之促效劑
WO2022246433A1 (en)	2021-05-18	2022-11-24	University Of Tennessee Research Foundation	Antibody-peptide fusion proteins for treating amyloid disorders
BR112023024494A2 (pt)	2021-05-24	2024-02-06	Humabs Biomed Sa	Polipeptídeos engenheirados
US20230036592A1 (en)	2021-06-03	2023-02-02	Surface Oncology, Inc.	Methods of treating cancer with an anti-cd39 antibody and pembrolizumab
TW202306994A (zh)	2021-06-04	2023-02-16	日商中外製藥股份有限公司	抗ddr2抗體及其用途
EP4355783A1 (en)	2021-06-16	2024-04-24	Alector LLC	Monovalent anti-mertk antibodies and methods of use thereof
JP2024527262A (ja)	2021-06-16	2024-07-24	アレクトルエルエルシー	二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
WO2022263638A1 (en)	2021-06-17	2022-12-22	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
JP2024526103A (ja)	2021-06-17	2024-07-17	ジェネンテック，インコーポレイテッド	抗ユビキチン化抗体および使用方法
CN117500829A (zh)	2021-06-18	2024-02-02	豪夫迈·罗氏有限公司	双特异性抗ccl2抗体
AU2022294106A1 (en)	2021-06-18	2024-01-25	Therini Bio, Inc.	ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
CA3220353A1 (en)	2021-06-25	2022-12-29	Chugai Seiyaku Kabushiki Kaisha	Use of anti-ctla-4 antibody
CR20240026A (es)	2021-06-25	2024-03-14	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-ctla-4
TW202306985A (zh)	2021-07-12	2023-02-16	美商建南德克公司	降低抗體－脂酶結合之結構
CA3224853A1 (en)	2021-07-14	2023-01-19	Gautham GAMPA	Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
CA3226100A1 (en)	2021-07-21	2023-01-26	Phillip S. KIM	Linker polypeptides
JP2024526880A (ja)	2021-07-22	2024-07-19	ジェネンテック，インコーポレイテッド	脳標的化組成物及びその使用方法
AU2022315528A1 (en)	2021-07-22	2023-10-19	F. Hoffmann-La Roche Ag	Heterodimeric fc domain antibodies
CN117794953A (zh)	2021-08-03	2024-03-29	豪夫迈·罗氏有限公司	双特异性抗体及使用方法
KR20240045314A (ko)	2021-08-18	2024-04-05	필립모리스 프로덕츠 에스.에이.	항체 및 이의 항원 결합 단편
JP2024534067A (ja)	2021-08-19	2024-09-18	エフ．ホフマン－ラロシュアーゲー	多価抗バリアントｆｃ領域抗体および使用方法
GB202111905D0 (en)	2021-08-19	2021-10-06	UCB Biopharma SRL	Antibodies
TW202315895A (zh)	2021-08-27	2023-04-16	瑞士商休曼生物醫藥股份公司	經工程化的組成物
IL310382A (en)	2021-08-27	2024-03-01	Genentech Inc	Methods for treating tau pathologies
TW202325727A (zh)	2021-08-30	2023-07-01	美商建南德克公司	抗聚泛素多特異性抗體
WO2023034871A1 (en)	2021-09-01	2023-03-09	Vir Biotechnology, Inc.	High concentration antibody therapies for sars-cov-2 infection
CA3230613A1 (en)	2021-09-01	2023-03-09	Daren J. AUSTIN	Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023036815A1 (en)	2021-09-07	2023-03-16	Etablissement Francais Du Sang	Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
WO2023039442A1 (en)	2021-09-08	2023-03-16	Vir Biotechnology, Inc.	Broadly neutralizing antibody combination therapies for sars-cov-2 infection
JPWO2023053282A1 (da)	2021-09-29	2023-04-06
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
KR20240082388A (ko)	2021-10-08	2024-06-10	추가이 세이야쿠 가부시키가이샤	프리필드 시린지 제제의 조제 방법
WO2023069919A1 (en)	2021-10-19	2023-04-27	Alector Llc	Anti-cd300lb antibodies and methods of use thereof
AU2022379952A1 (en)	2021-11-05	2024-05-16	Mab Biotec, Inc.	Monoclonal antibodies against carcinoembryonic antigens, and their uses
WO2023081898A1 (en)	2021-11-08	2023-05-11	Alector Llc	Soluble cd33 as a biomarker for anti-cd33 efficacy
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
MX2024005680A (es)	2021-11-16	2024-05-30	Genentech Inc	Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
TW202334202A (zh)	2021-11-16	2023-09-01	瑞士商Ａｃ免疫有限公司	用於治療和診斷的新分子
KR20240116755A (ko)	2021-12-17	2024-07-30	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
WO2023109901A1 (en)	2021-12-17	2023-06-22	Shanghai Henlius Biotech, Inc.	Anti-ox40 antibodies and methods of use
TW202340251A (zh)	2022-01-19	2023-10-16	美商建南德克公司	抗ｎｏｔｃｈ２抗體及結合物及其使用方法
EP4469159A1 (en)	2022-01-27	2024-12-04	The Rockefeller University	Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
EP4479426A1 (en)	2022-02-16	2024-12-25	AC Immune SA	Humanized anti-tdp-43 binding molecules and uses thereof
EP4482523A1 (en)	2022-02-23	2025-01-01	Alector LLC	Methods of use of anti-trem2 antibodies
EP4238988A1 (en)	2022-03-01	2023-09-06	Consejo Superior De Investigaciones Científicas	Antibodies against sars-cov-2 and uses thereof
EP4496631A1 (en)	2022-03-23	2025-01-29	F. Hoffmann-La Roche AG	Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023179740A1 (en)	2022-03-25	2023-09-28	Shanghai Henlius Biotech , Inc.	Anti-msln antibodies and methods of use
WO2023191816A1 (en)	2022-04-01	2023-10-05	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025513799A (ja)	2022-04-08	2025-04-30	エイシーイミューンソシエテアノニム	抗ｔｄｐ－４３結合分子
WO2023201256A1 (en)	2022-04-12	2023-10-19	Vir Biotechnology, Inc.	High dose antibody therapies for sars-cov-2 infection
TW202404637A (zh)	2022-04-13	2024-02-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
EP4508087A1 (en)	2022-04-13	2025-02-19	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
TW202519266A (zh)	2022-04-13	2025-05-16	美商建南德克公司	莫蘇妥珠單抗之醫藥組成物及其使用方法
CA3243581A1 (en)	2022-04-20	2023-10-26	Kantonsspital St. Gallen	ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES
PE20242350A1 (es)	2022-05-03	2024-12-16	Genentech Inc	Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
WO2023213969A1 (en)	2022-05-05	2023-11-09	Juno Therapeutics Gmbh	Viral-binding protein and related reagents, articles, and methods of use
AR129268A1 (es)	2022-05-11	2024-08-07	Hoffmann La Roche	Anticuerpo que se une a vegf-a e il6 y métodos de uso
CA3251472A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	DOSAGE FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
WO2023230448A1 (en)	2022-05-23	2023-11-30	Vir Biotechnology, Inc.	Combination immunotherapy for influenza
AR129399A1 (es)	2022-05-23	2024-08-21	Vir Biotechnology Inc	Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos
CN119907679A (zh)	2022-05-23	2025-04-29	胡默波斯生物医学公司	针对流感神经氨酸苷酶的广谱中和抗体
KR20250022049A (ko)	2022-06-07	2025-02-14	제넨테크, 인크.	항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
US20250382354A1 (en)	2022-06-08	2025-12-18	Institute For Research In Biomedicine (Irb)	Cross-specific antibodies, uses and methods for discovery thereof
WO2023245078A1 (en)	2022-06-15	2023-12-21	Humabs Biomed Sa	Anti-parvovirus antibodies and uses thereof
KR20250024900A (ko)	2022-06-17	2025-02-20	제넨테크, 인크.	친화성 크로마토그래피 정제 단계의 수율을 향상시키기 위한 코스모트로프의 용도
WO2024006472A1 (en)	2022-06-30	2024-01-04	Vir Biotechnology, Inc.	Antibodies that bind to multiple sarbecoviruses
CN119585308A (zh)	2022-07-13	2025-03-07	基因泰克公司	针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
EP4558524A1 (en)	2022-07-19	2025-05-28	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CR20250056A (es)	2022-07-22	2025-03-19	Genentech Inc	Moléculas de unión al antígeno anti-steap1 y sus usos.
EP4562034A1 (en)	2022-07-27	2025-06-04	Humabs Biomed SA	Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
CN119866348A (zh)	2022-07-29	2025-04-22	艾莱克特有限责任公司	抗gpnmb抗体及其使用方法
CA3265385A1 (en)	2022-08-22	2024-02-29	Abdera Therapeutics Inc.	DLL3 BINDING MOLECULES AND THEIR USES
WO2024052922A1 (en)	2022-09-11	2024-03-14	Yeda Research And Development Co. Ltd.	Anti-klk4 antibodies and uses thereof
WO2024068996A1 (en)	2022-09-30	2024-04-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4598959A1 (en)	2022-10-07	2025-08-13	Genentech, Inc.	Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024079074A1 (en)	2022-10-10	2024-04-18	Universite D'aix Marseille	ANTI-sCD146 ANTIBODIES AND USES THEREOF
WO2024086796A1 (en)	2022-10-20	2024-04-25	Alector Llc	Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024091991A1 (en)	2022-10-25	2024-05-02	Genentech, Inc.	Therapeutic and diagnostic methods for multiple myeloma
AU2023375342A1 (en)	2022-11-08	2025-04-24	F. Hoffmann-La Roche Ag	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100200A1 (en)	2022-11-09	2024-05-16	Cis Pharma Ag	Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024104988A1 (en)	2022-11-15	2024-05-23	F. Hoffmann-La Roche Ag	Recombinant binding proteins with activatable effector domain
WO2024107749A1 (en)	2022-11-16	2024-05-23	Attralus, Inc.	Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
WO2024112818A1 (en)	2022-11-22	2024-05-30	Humabs Biomed Sa	Engineered anti-sars-cov-2 antibodies and uses thereof
CN120265651A (zh)	2022-11-25	2025-07-04	中外制药株式会社	用于生产蛋白质的方法
WO2024118998A2 (en)	2022-12-01	2024-06-06	Vir Biotechnology, Inc.	Engineered anti-sars-cov-2 antibodies and methods of using the same
CN119998314A (zh)	2022-12-08	2025-05-13	长春百克生物科技股份公司	特异性结合rsv的抗体
WO2024121632A1 (en)	2022-12-09	2024-06-13	Crispr Therapeutics Ag	Use of anti-cd117 antibody drug conjugate (adc)
CN120344665A (zh)	2022-12-27	2025-07-18	中外制药株式会社	具有受控缔合的多肽
EP4646270A2 (en)	2023-01-06	2025-11-12	Alector LLC	Anti-il18 binding protein antibodies and methods of use thereof
AR131638A1 (es)	2023-01-18	2025-04-16	Genentech Inc	Anticuerpos multiespecíficos y usos de estos
WO2024182781A1 (en)	2023-03-02	2024-09-06	Vir Biotechnology, Inc.	Coronavirus compositions and uses thereof
WO2024184494A1 (en)	2023-03-08	2024-09-12	Ac Immune Sa	Anti-tdp-43 binding molecules and uses thereof
CN120858109A (zh)	2023-03-10	2025-10-28	基因泰克公司	与蛋白酶的融合物及其用途
CN120835901A (zh)	2023-03-13	2025-10-24	豪夫迈·罗氏有限公司	采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
AU2024248331A1 (en)	2023-03-31	2025-10-09	Genentech, Inc.	Anti-alpha v beta 8 integrin antibodies and methods of use
TW202446788A (zh)	2023-04-10	2024-12-01	美商維爾生物科技公司	結合多種薩貝冠狀病毒之抗體
CN120936723A (zh)	2023-04-13	2025-11-11	豪夫迈·罗氏有限公司	改进的重组多腺苷酸化信号序列及其用途
WO2024220546A2 (en)	2023-04-17	2024-10-24	Peak Bio, Inc.	Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
AU2024270495A1 (en)	2023-05-05	2025-10-09	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR132623A1 (es)	2023-05-08	2025-07-16	Hoffmann La Roche	PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
AU2024268933A1 (en)	2023-05-10	2025-11-20	Chugai Seiyaku Kabushiki Kaisha	Methods and compositions for treating cancer
AR132687A1 (es)	2023-05-16	2025-07-23	Hoffmann La Roche	Inmunoconjugados de il-2 regulados por pd-1 y sus usos
WO2024263845A1 (en)	2023-06-22	2024-12-26	Genentech, Inc.	Treatment of multiple myeloma
WO2024263761A1 (en)	2023-06-22	2024-12-26	Genentech, Inc.	Antibodies and uses thereof
WO2025010424A1 (en)	2023-07-06	2025-01-09	Vir Biotechnology, Inc.	Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en)	2023-07-13	2025-01-16	Vir Biotechnology, Inc.	Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2025017153A1 (en)	2023-07-19	2025-01-23	F. Hoffmann-La Roche Ag	Dsfv as an igg fragment format and methods of production and labelling thereof
WO2025032071A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Anti-a-beta protein antibodies, methods and uses thereof
AR133909A1 (es)	2023-09-25	2025-11-12	Hoffmann La Roche	ANTICUERPO QUE SE UNE A C3bBb
WO2025072726A1 (en)	2023-09-29	2025-04-03	Trex Bio, Inc.	Tnf-alpha variant fusion molecules
WO2025099120A1 (en)	2023-11-09	2025-05-15	F. Hoffmann-La Roche Ag	Multispecific antibodies with conditional activity
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025117848A1 (en)	2023-12-01	2025-06-05	Genentech, Inc.	Low-viscosity variants of antibodies
WO2025113643A1 (en)	2023-12-01	2025-06-05	Gilead Sciences Inc.	Anti-fap-light fusion protein and use thereof
WO2025125386A1 (en)	2023-12-14	2025-06-19	F. Hoffmann-La Roche Ag	Antibodies that bind to folr1 and methods of use
WO2025129010A1 (en)	2023-12-14	2025-06-19	Genentech, Inc.	Methods of structure determination using antibodies
WO2025133042A2 (en)	2023-12-22	2025-06-26	F. Hoffmann-La Roche Ag	Activatable fusion proteins and methods of use
NL2037390B1 (en)	2024-04-03	2025-10-13	Academisch Ziekenhuis Leiden	Selection and characterization of a peptide-based complement activator
CN121175334A (zh)	2024-04-13	2025-12-19	益免安协公司	在治疗癌症中的使用pd-l1抑制剂的新辅助免疫疗法
WO2025226834A1 (en)	2024-04-23	2025-10-30	Attovia Therapeutics, Inc.	Il31-binding polypeptides and uses thereof
WO2025226808A1 (en)	2024-04-24	2025-10-30	Genentech, Inc.	Compositions and methods of treating lupus nephritis
WO2025233867A1 (en)	2024-05-10	2025-11-13	Adaptam Therapeutics, S.L.	Anti-siglec-9 antibodies and uses thereof
WO2025238187A1 (en)	2024-05-15	2025-11-20	Cis Biopharma Ag	Immunoconjugates targeting l1-cam
WO2025237931A1 (en)	2024-05-15	2025-11-20	F. Hoffmann-La Roche Ag	Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
WO2025238135A2 (en)	2024-05-17	2025-11-20	UCB Biopharma SRL	Antibody with binding specificity for il-11
WO2025238133A1 (en)	2024-05-17	2025-11-20	UCB Biopharma SRL	Multispecific antibody with binding specificity for il-11 and il-17
WO2025250969A1 (en)	2024-05-31	2025-12-04	Vertex Pharmaceuticals Incorporated	Anti-cd74 antibodies, conjugates and uses thereof
WO2025259871A1 (en)	2024-06-14	2025-12-18	Gilead Sciences, Inc.	Anti-ccr8 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4963495A (en) *	1984-10-05	1990-10-16	Genentech, Inc.	Secretion of heterologous proteins
US5232840A (en) *	1986-03-27	1993-08-03	Monsanto Company	Enhanced protein production in bacteria by employing a novel ribosome binding site

1995
- 1995-03-01 US US08/398,615 patent/US5840523A/en not_active Expired - Lifetime
1996
- 1996-02-27 NZ NZ303619A patent/NZ303619A/en not_active IP Right Cessation
- 1996-02-27 ES ES96906659T patent/ES2285711T3/es not_active Expired - Lifetime
- 1996-02-27 CA CA002213813A patent/CA2213813C/en not_active Expired - Lifetime
- 1996-02-27 AT AT96906659T patent/ATE358181T1/de active
- 1996-02-27 DE DE69636996T patent/DE69636996T2/de not_active Expired - Lifetime
- 1996-02-27 RU RU97116138/13A patent/RU2208639C2/ru active
- 1996-02-27 BR BRPI9607464-7A patent/BR9607464B1/pt not_active IP Right Cessation
- 1996-02-27 EP EP96906659A patent/EP0815246B1/en not_active Expired - Lifetime
- 1996-02-27 AU AU49984/96A patent/AU701476B2/en not_active Expired
- 1996-02-27 JP JP52643696A patent/JP3375970B2/ja not_active Expired - Lifetime
- 1996-02-27 DK DK96906659T patent/DK0815246T3/da active
- 1996-02-27 WO PCT/US1996/002858 patent/WO1996027016A1/en not_active Ceased
- 1996-02-27 CN CNB961930578A patent/CN1154736C/zh not_active Expired - Lifetime
- 1996-02-29 IL IL11731496A patent/IL117314A0/xx not_active IP Right Cessation
- 1996-03-01 ZA ZA9601688A patent/ZA961688B/xx unknown
1997
- 1997-08-29 NO NO19973985A patent/NO324920B1/no not_active IP Right Cessation
- 1997-08-29 FI FI973559A patent/FI120357B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO324920B1 (no)	2008-01-07
CN1180379A (zh)	1998-04-29
FI973559L (fi)	1997-10-29
IL117314A0 (en)	1996-06-18
AU701476B2 (en)	1999-01-28
DE69636996T2 (de)	2007-12-06
ES2285711T3 (es)	2007-11-16
FI120357B (fi)	2009-09-30
WO1996027016A1 (en)	1996-09-06
CA2213813A1 (en)	1996-09-06
EP0815246A1 (en)	1998-01-07
NO973985D0 (no)	1997-08-29
EP0815246B1 (en)	2007-03-28
BR9607464B1 (pt)	2009-01-13
ATE358181T1 (de)	2007-04-15
AU4998496A (en)	1996-09-18
JP3375970B2 (ja)	2003-02-10
DE69636996D1 (de)	2007-05-10
NO973985L (no)	1997-10-29
JPH10507368A (ja)	1998-07-21
FI973559A0 (fi)	1997-08-29
CN1154736C (zh)	2004-06-23
US5840523A (en)	1998-11-24
MX9706607A (es)	1997-11-29
RU2208639C2 (ru)	2003-07-20
CA2213813C (en)	2008-05-27
BR9607464A (pt)	1997-12-23
NZ303619A (en)	2000-02-28
ZA961688B (en)	1997-09-01

Publication	Publication Date	Title
DK0815246T3 (da)	2007-08-06	Fremgangsmåder og sammensætninger til sekretion af heterologe polypeptider
DK547185D0 (da)	1985-11-26	Vektorer til ekspression af hirudin, transformerede celler og fremgangsmaade til fremstilling af hirudin
DK20984A (da)	1984-07-20	Fremgangsmaade til fremstilling af et oensket modent protein i en hvirveldyrvaertscelle, polycistromisk udtrykkelsesvektor for det oenskede protein, fremgangsmaade til selektering af transfilerede hvirveldyrceller og hvirveldyrcellekultur transformeret med vektoren
IL130190A0 (en)	2000-06-01	Methods and compositions for polypeptide engineering
DK0832258T3 (da)	2002-08-12	Opstrøms aktivatorsekvenser og rekombinante promotorsekvenser, der er funktionelle i Yarrowia og vektorer indeholdende disse
BR9914278A (pt)	2001-06-19	Cepa de chrysosporium mutante, construção de ácido nucléico, cepa microbiana recombinante, métodos para produzir um polipeptìdeo de interesse, e para produzir uma cepa de chrysosporium mutante, e, xilanase de chrysosporium da famìlia de xilanases f,
DK0610046T3 (da)	2006-03-27	Ekspressionsvektorer kodende for bispecifikke fusionsproteiner og fremgangsmåder til fremstilling af biologisk aktive, bispecifikke fusionsproteiner i en pattedyrscelle
ES2125224T3 (es)	1999-03-01	Mutantes de subtilisina.
EP0608261A4 (en)	1995-03-15	COMPOSITION OF AN IMMUNREACTIVE HEPATITIS C VIRUS POLYPEPTIDE.
DK0672141T3 (da)	2003-06-10	Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
GB9712512D0 (en)	1997-08-20	A method for in vitro molecular evolution of protein function
IL114809A0 (en)	1995-12-08	Mutant br96 antibodies
NZ512078A (en)	2004-01-30	Nucleic acid constructs comprising a hepatitis B core antigen and a cytolytic T lymphocyte antigen for genetic immunization
NO982207D0 (no)	1998-05-14	Fremmedproteinsekresjonsvektorer, transformerte mikroorganismer og fremgangsmÕte for fremstilling av hirudiner
DK1272633T3 (da)	2011-05-23	Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi
EP0726944A4 (en)	1997-01-29	GLYCOSYLATED AND NON-GLYCOSYLATED PROTEINS, BACTERICIDES AND INCREASING PERMEABILITY, AND PROCESS FOR PRODUCING THE SAME
DE3853932D1 (de)	1995-07-13	Hochreprimierbare Expressionskontrollsequenzen.
MX9706290A (es)	1998-02-28	Secuencias amplificadoras, vectores que portan estas secuencias y sus utilizaciones en composiciones para la expresion de secuencias nucleotidicas en celulas transfectadas, aplicaciones terapeuticas y vacunales.
DK0443476T3 (da)	1996-05-13	Termostabile mutanter af neutral protease og midler til fremstilling af disse
FR2692282B1 (fr)	1995-07-13	Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
DK313389D0 (da)	1989-06-23	Fremgangsmaade til opdraet af fisk og apparat til anvendelse derved
EP0179412A3 (en)	1988-08-24	Antigenic peptide compounds
DK0826054T3 (da)	2004-04-19	Ekspression af glycosyltransferase i Aspergillus
DK0385391T3 (da)	2000-05-29	Ekspressionsvektorer til syntese af proteiner i Schizosaccharomyces pombe
DK0514405T3 (da)	1995-07-10	Stamme RAL-4, der er anvendelig til fremstilling af små proteiner og peptider